Answers are grounded in this paper and cite their sources.
Colorectal cancer (CRC) is a leading cause of cancer mortality worldwide. Interleukin-1β (IL-1β) is a pro-inflammatory cytokine upregulated in many tumors, including CRC. In the tumor microenvironment (TME) it promotes angiogenesis, immunosuppression, and resistance to chemotherapy. We aimed to elucidate the correlation between TME IL-1β and colon microbiotic changes during CRC progression and approach inhibition of IL-1β in combination with standard chemotherapy as a therapeutic strategy. Using an orthotopic mouse model of CRC, we compared tumor growth, metastatic spread, immune infiltration and microbiome composition in control and IL-1β knockout mice. We studied the effects of IL-1β neutralization in combination with FOLFOX chemotherapy on CRC progression. IL-1β promotes CRC progression by enhancing pro-inflammatory signaling, associated with recruiting myeloid cells and microbiome dysbiosis. Its deficiency delayed tumor growth and reduced metastasis that was accompanied by increased infiltration of antigen-presenting cells and changes in gut microbiota. FOLFOX chemotherapy exacerbated systemic and local inflammation, facilitating liver metastasis, where the addition of anti-IL-1β antibodies significantly reduced FOLFOX-induced inflammation and enhanced anti-tumor immunity. IL-1β from the TME links microbiome dysbiosis, tumor-promoting inflammation and poor chemotherapy outcomes in CRC. Combining IL-1β inhibition with standard FOLFOX chemotherapy represents a promising therapeutic approach to CRC treatment.
No takes yet. Share an insight, caveat, or question.
Machluf-Katz et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: